On June 30, 2025, Unicycive Therapeutics, Inc. announced that the FDA issued a Complete Response Letter for its New Drug Application for oxylanthanum carbonate to treat hyperphosphatemia, indicating that it needs further data for approval. The company expects to report having approximately $20.7 million in cash and cash equivalents as of the same date.